Bioequivalence study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

Trial Identifier: D168AC00002
Sponsor: AstraZeneca
NCTID:: NCT03138356
Start Date: May 2017
Primary Completion Date: November 2017
Study Completion Date: November 2017
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
English Translation

Trial Locations

Country Location
United Kingdom Harrow, United Kingdom, HA1 3UJ